

Data Sharing Statement

Dummer. Final 5-Year Follow-Up Results Evaluating Neoadjuvant Talimogene Laherparepvec Plus Surgery in Advanced Melanoma. *JAMA Oncol.* Published August 10, 2023.
doi:10.1001/jamaoncol.2023.2789

Data

Data available: Yes

Data types: Deidentified participant data, Data dictionary

How to access data: <https://www.amgen.com/science/clinical-trials/clinical-data-transparency-practices/clinical-trial-data-sharing-request>

When available: beginning date: 10-29-2023

Supporting Documents

Document types: None

Additional Information

Who can access the data: Qualified medical/scientific researchers requesting the data, researchers whose proposed use of the data has been approved

Types of analyses: n/a

Mechanisms of data availability: after approval of a proposal

Any additional restrictions: Following the approval of a data sharing request and the signing of the agreement, Amgen will de-identify patient-level data and anonymize documents in accordance with local legal and ethical regulations. The de-identified patient level data will be provided directly to the researcher in a secure manner, and the researcher is responsible for protecting the confidentiality and integrity of the data while the research is conducted.